litlas
Log inCreate account

Peter C. Taylor

Active 1985–2025

152
Papers
21,177
Citations
86
h-index
147
i10-index

Citations

Citations per year for Peter C. Taylor1948: 1 citations1988: 1 citations1989: 1 citations1990: 2 citations1991: 3 citations1992: 9 citations1993: 2 citations1994: 5 citations1995: 15 citations1996: 14 citations1997: 34 citations1998: 32 citations1999: 34 citations2000: 71 citations2001: 129 citations2002: 111 citations2003: 121 citations2004: 127 citations2005: 98 citations2006: 107 citations2007: 124 citations2008: 147 citations2009: 155 citations2010: 147 citations2011: 120 citations2012: 126 citations2013: 133 citations2014: 109 citations2015: 132 citations2016: 109 citations2017: 135 citations2018: 164 citations2019: 505 citations2020: 782 citations2021: 805 citations2022: 716 citations2023: 573 citations2024: 810 citations2025: 467 citations2026: 15 citations1949–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,076 citing papers, 19.7% of this breakdownUnited Kingdom: 1,191 citing papers, 11.3% of this breakdownChina: 674 citing papers, 6.4% of this breakdownGermany: 560 citing papers, 5.3% of this breakdownItaly: 516 citing papers, 4.9% of this breakdownFrance: 444 citing papers, 4.2% of this breakdownNetherlands: 393 citing papers, 3.7% of this breakdownJapan: 361 citing papers, 3.4% of this breakdownCanada: 354 citing papers, 3.4% of this breakdownAustralia: 288 citing papers, 2.8% of this breakdownSpain: 283 citing papers, 2.7% of this breakdownSweden: 251 citing papers, 2.4% of this breakdown
0%19.7%Other 29.8%

Institutions

Fields

  • Medicine66.3%
  • Biochemistry, Genetics and Molecular Biology14%
  • Immunology and Microbiology9.2%
  • Nursing4.1%
  • Neuroscience2.4%
  • Pharmacology, Toxicology and Pharmaceutics0.6%
  • Other3.4%

Topics

  • Rheumatoid Arthritis Research and Therapies11.1%
  • Systemic Lupus Erythematosus Research3.6%
  • Autoimmune and Inflammatory Disorders Research3.4%
  • Spondyloarthritis Studies and Treatments3.4%
  • Cytokine Signaling Pathways and Interactions2.5%
  • Monoclonal and Polyclonal Antibodies Research1.9%
  • Other74.1%

Coauthors

All papers

Open in search
  1. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

    Authors: Felice Rivellese, Anna E. A. Surace, Katriona Goldmann, Elisabetta Sciacca, Cankut Çubuk, Giovanni Giorli, Christopher R. John, Alessandra Nerviani, Liliane Fossati‐Jimack, Georgina Thorborn, Manzoor Ahmed, Edoardo Prediletto, S. Church, Briana M. Hudson, Sarah Warren, Paul McKeigue, Frances Humby, Michele Bombardieri, Michael R. Barnes, Myles Lewis, Costantino Pitzalis, the R4RA collaborative group, Felice Rivellese, Giovanni Giorli, Alessandra Nerviani, Liliane Fossati‐Jimack, Georgina Thorborn, Frances Humby, Michele Bombardieri, Myles Lewis, Patrick Durez, Maya H Buch, Hasan Rizvi, Arti Mahto, Carlomaurizio Montecucco, Bernard Lauwerys, Nora Ng, Pauline Ho, Vasco C. Romão, João Eurico Fonseca, Patrick Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar DasGupta, Alberto Cauli, Piero Reynolds, Juan D. Cañete, Julio Ramírez, Raquel Celis, Robert J. Moots, Peter C. Taylor, C J Edwards, John D. Isaacs, Peter Sasieni, Ernest Choy, Charlotte Thompson, Serena Bugatti, Mattia Bellan, Mattia Congia, Christopher Holroyd, Arthur G. Pratt, Laura White, Louise Warren, Joanna Peel, Rebecca Hands, Gaye Hadfield, Costantino Pitzalis - Nature Medicine 2022 cited by 279

  2. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

    Authors: Peter C. Taylor, Edward Keystone, Désirée van der Heijde, Michael E. Weinblatt, Liliana Morales, Jaime Reyes Gonzaga, S. S. Yаkushin, Taeko Ishii, Kahaku Emoto, Scott D. Beattie, Vipin Arora, C. Gaich, Terence Rooney, Douglas Schlichting, William L. Macias, Stephanie de Bono, Yoshiya Tanaka - New England Journal of Medicine 2017 cited by 951

  3. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

    Authors: Frances Humby, Patrick Durez, Maya H Buch, Myles Lewis, Hasan Rizvi, Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Arti Mahto, Carlomaurizio Montecucco, Bernard Lauwerys, Nora Ng, Pauline Ho, Michele Bombardieri, Vasco C. Romão, Patrick Verschueren, Stephen Kelly, Pier Paolo Sainaghi, Nagui Gendi, Bhaskar Dasgupta, Alberto Cauli, Piero Reynolds, Juan D. Cañete, Robert J. Moots, Peter C. Taylor, Christopher J Edwards, John D. Isaacs, Peter Sasieni, Ernest Choy, Costantino Pitzalis, Charlotte Thompson, Serena Bugatti, Mattia Bellan, Mattia Congia, Christopher Holroyd, Arthur G. Pratt, João Eurico Fonseca, Laura White, Louise Warren, Joanna Peel, Rebecca Hands, Liliane Fossati‐Jimack, Gaye Hadfield, Georgina Thorborn, Julio Ramírez, Raquel Celis - The Lancet 2021 cited by 315

  4. Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes

    Authors: Myles Lewis, Michael R. Barnes, Kevin Blighe, Katriona Goldmann, Sharmila Rana, Jason A. Hackney, Nandhini Ramamoorthi, Christopher R. John, David Watson, Sarah Kummerfeld, Rebecca Hands, Sudeh Riahi, Vidalba Rocher-Ros, Felice Rivellese, Frances Humby, Stephen Kelly, Michele Bombardieri, Nora Ng, Maria DiCicco, Désirée van der Heijde, Robert Landewé, Annette H M van der Helm–van Mil, Alberto Cauli, Iain B. McInnes, Christopher D. Buckley, Ernest Choy, Peter C. Taylor, Michael J. Townsend, Costantino Pitzalis - Cell Reports 2019 cited by 416

  5. Neutralizing monoclonal antibodies for treatment of COVID-19

    Authors: Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, Inmaculada de la Torre, Kevin Winthrop, Robert Gottlieb - Nature reviews. Immunology 2021 cited by 794

  6. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients

    Authors: Frances Humby, Myles Lewis, Nandhini Ramamoorthi, Jason A. Hackney, Michael R. Barnes, Michele Bombardieri, Audi Setiadi, Stephen Kelly, Fabiola Bene, Maria DiCicco, Sudeh Riahi, Vidalba Rocher, Nora Ng, Ilias Lazarou, Rebecca Hands, Désirée van der Heijde, Robert Landewé, Annette H M van der Helm–van Mil, Alberto Cauli, Iain B. McInnes, Christopher D. Buckley, Ernest Choy, Peter C. Taylor, Michael J. Townsend, Costantino Pitzalis - Annals of the Rheumatic Diseases 2019 cited by 326

  7. The Jak/STAT pathway: A focus on pain in rheumatoid arthritis

    Authors: Lee S. Simon, Peter C. Taylor, Ernest Choy, Anthony Sebba, Amanda Quebe, Kelly L. Knopp, Frank Porreca - Seminars in Arthritis and Rheumatism 2020 cited by 215

  8. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

    Authors: Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Josef S Smolen, Walter Deberdt, Maher Issa, Jorge Ross Terrés, Natalia Bello, Kevin Winthrop - Annals of the Rheumatic Diseases 2021 cited by 160

  9. Anti-TNF therapy: past, present and future

    Authors: Claudia Monaco, Jagdeep Nanchahal, Peter C. Taylor, Marc Feldmann - International Immunology 2014 cited by 571

  10. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

    Authors: Iain B. McInnes, Nicole L Byers, Richard E. Higgs, Jonathan Lee, William L. Macias, Songqing Na, Robert Ortmann, Guilherme Rocha, Terence Rooney, Thomas S. Wehrman, Xin Zhang, Steven H. Zuckerman, Peter C. Taylor - Arthritis Research & Therapy 2019 cited by 281

  11. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

    Authors: Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltán Szekanecz, Ricardo Machado Xavier, John D. Isaacs, Sander Strengholt, Julie Parmentier, Ralph Lippe, Yoshiya Tanaka - Lara D. Veeken 2023 cited by 93

  12. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial

    Authors: José María Álvaro‐Gracia, Juan Ángel Jover, Rosario García‐Vicuña, Luis Carreño, Alberto Alonso, Sara Marsal, Francisco J. Blanco, Víctor M. Martínez‐Taboada, Peter C. Taylor, Cristina Martín-Martín, Olga DelaRosa, Ignacio Tagarro, Federico Díaz‐González - Annals of the Rheumatic Diseases 2016 cited by 263

  13. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review

    Authors: Peter C. Taylor, Fabiola Atzeni, Alejandro Balsa, Laure Gossec, Ulf Müller‐Ladner, Janet Pope - Journal of Clinical Medicine 2021 cited by 109

  14. Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes

    Authors: Kelsey N. Thompson, Kevin S. Bonham, Nicholas E. Ilott, Graham J. Britton, Paula Colmenero, Samuel J. Bullers, Lauren J. McIver, Siyuan Ma, Long H. Nguyen, Andrew Filer, India Brough, Claire Pearson, Caroline Moussa, Vinod Kumar, Lilian H. Lam, Matthew Jackson, April Pawluk, Serafim Kiriakidis, Peter C. Taylor, Lucy R. Wedderburn, Brian D. Marsden, Stephen P. Young, Dan R. Littman, Jeremiah J. Faith, Arthur G. Pratt, Paul Bowness, Karim Raza, Fiona Powrie, Curtis Huttenhower, Coziana Ciurtin, Claudia Mauri - Science Translational Medicine 2023 cited by 49

  15. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis

    Authors: Kathleen Weisel, Scott B. Berger, Katie Thorn, Peter C. Taylor, Charles Peterfy, Hilary K. Siddall, Debra Tompson, Susanne Wang, Emilia Quattrocchi, Susan W. Burriss, Jochen Walter, Paul P. Tak - Arthritis Research & Therapy 2021 cited by 89

  16. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials

    Authors: Felice Rivellese, Alessandra Nerviani, Giovanni Giorli, Louise Warren, Edyta Jaworska, Michele Bombardieri, Myles Lewis, Frances Humby, Arthur G. Pratt, Andrew Filer, Nagui Gendi, Alberto Cauli, Ernest Choy, Iain B. McInnes, Patrick Durez, Christopher J Edwards, Maya H Buch, Elisa Gremese, Peter C. Taylor, Nora Ng, Juan D. Cañete, Sabrina Raizada, Neil D McKay, Deepak R. Jadon, Pier Paolo Sainaghi, Richard Stratton, Michael R. Ehrenstein, Pauline Ho, Joaquim Polido‐Pereira, Bhaskar Dasgupta, Claire Gorman, James Galloway, Hector Chinoy, Désirée van der Heijde, Peter Sasieni, Anne Barton, Costantino Pitzalis, Ahmed S Zayat, Ana Rita Marinho Machado, Andrea Cuervo, Arti Mahto, Cankut Çubuk, Charlotte Rawlings, Chijioke H Mosanya, Christopher D. Buckley, Chris Holroyd, Debbie Maskall, Francesco Carlucci, Georgina Thorborn, Gina Tan, Gloria Lliso-Ribera, Hasan Rizvi, Joanna Peel, João Eurico Fonseca, John D. Isaacs, Julio Ramírez, Laurent Méric de Bellefon, Liliane Fossati-Jimak, Mary Ng’endo Githinji, Mattia Congia, Neal L. Millar, Nirupam Purkayastha, Raquel Celis, Rakhi Seth, Rebecca Hands-Greenwood, Robert Landewé, Simone Perniola, Stefano Alivernini, Stefano Marcia, Stefano Marini, Stephen Kelly, Vasco C. Romão - The Lancet Rheumatology 2023 cited by 68

  17. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

    Authors: Edward Keystone, Peter C. Taylor, Edit Drescher, Douglas Schlichting, Scott D. Beattie, Pierre‐Yves Berclaz, Chin H. Lee, Rosanne Fidelus-Gort, Monica Luchi, Terence Rooney, William L. Macias, Mark C. Genovese - Annals of the Rheumatic Diseases 2014 cited by 282

  18. Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

    Authors: Peter C. Taylor, Michael E. Weinblatt, Gerd R Burmester, Terence Rooney, Sarah Witt, Chad D. Walls, Maher Issa, Claudia A. Salinas, Chadi Saifan, Xin Zhang, Anabela Cardoso, Miguel Á. González‐Gay, Tsutomu Takeuchi - Arthritis & Rheumatology 2019 cited by 177

  19. Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC)

    Authors: Gloria Lliso-Ribera, Frances Humby, Myles Lewis, Alessandra Nerviani, Daniele Mauro, Felice Rivellese, Stephen Kelly, Rebecca Hands, Fabiola Bene, Nandhini Ramamoorthi, Jason A. Hackney, Alberto Cauli, Ernest Choy, Andrew Filer, Peter C. Taylor, Iain B. McInnes, Michael J. Townsend, Costantino Pitzalis - Annals of the Rheumatic Diseases 2019 cited by 128

  20. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans

    Authors: David R. Owen, Nehal Narayan, Lisa Wells, Luke M. Healy, Erica Smyth, Eugenii A. Rabiner, Dylan A. Galloway, John B. Williams, Joshua Lehr, Harpreet Mandhair, Laura A. N. Peferoen, Peter C. Taylor, Sandra Amor, Jack P. Antel, Paul M. Matthews, Craig S. Moore - Journal of Cerebral Blood Flow & Metabolism 2017 cited by 199

  21. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)

    Authors: René Westhovens, Peter C. Taylor, Rieke Alten, Д. Е. Павлова, Favio Enríquez-Sosa, Minodora Mazur, Maria Greenwald, Annegret Van der Aa, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison - Annals of the Rheumatic Diseases 2016 cited by 234

  22. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

    Authors: Peter C. Taylor - Lara D. Veeken 2018 cited by 171

  23. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

    Authors: Daniel C. Baumgart, L. Misery, Sue Naeyaert, Peter C. Taylor - Frontiers in Pharmacology 2019 cited by 134

  24. Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

    Authors: Peter C. Taylor, Yvonne Lee, Roy Fleischmann, Tsutomu Takeuchi, Elizabeth L. Perkins, Bruno Fautrel, Baojin Zhu, Amanda Quebe, C. Gaich, Xiang Zhang, Christina Dickson, Douglas Schlichting, Himanshu J. Patel, Frédérick Durand, Paul Emery - Journal of Clinical Medicine 2019 cited by 91